重组病毒载体新型冠状病毒疫苗的临床研究进展

Advances in clinical research of virus vector-based COVID-19 vaccines

2019年底的新冠疫情加速了全球各研究机构对新冠疫苗的研发。正在进行临床试验的多种技术平台的新冠疫苗中,重组病毒载体类疫苗表现出较好的免疫原性优势和效力,但同时出现的疫苗安全性和载体预存抗体等问题也不容忽视。本文将概述重组载体疫苗的设计理念和发展历程,梳理当前不同重组病毒载体新冠疫苗的临床研究进展,并阐述其面临的主要挑战和未来的发展方向,以期为重组载体类疫苗的研究提供借鉴。

The COVID-19 outbreak at the end of 2019 has accelerated the development and research for COVID-19 vaccines worldwide.Among the COVID-19 vaccines in clinical trials developed via different platforms,recombinant virus vector-based vaccines have shown excellent immunogenicity and efficacy.However,at the same time,there are serious issues such as vaccine safety and pre-existing antibodies against vectors.This article summarizes the design concept and development history of recombinant virus vector-based vaccines,and focuses on the progress in the clinical studies of vector-based COVID-19 vaccines as well as the challenges,in order to provide reference for the research of recombinant vector-based vaccines.